Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication
ChiCTR2000040051Phase 4Recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Helicobacter pylori infection comparing Bismuth quadruple therapy, Rabeprazole + amoxicillin dual therapy and Rabeprazole + furazolidone dual therapy (3 arms). Primary endpoint: eradication rate. Started Apr 2020; status: recruiting.
02
Drugs
rabeprazoleamoxicillinfurazolidonebismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2000040051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040051.